A series of 1-phenyl-3-azabicyclo[3.1.0]hexanes were synthesized as more conformationally restricted prototypical σ ligands 3-phenylpiperidines with the aim to developing new σ ligands. Compared with 3-phenylpiperidines reported by Largent et al., binding data showed that conformational restriction was not detrimental for σ receptor affinity. Specifically, except for secondary amine 4, all racemic 1-phenyl-3-azabicyclo[3.1.0]hexane derivatives (12-19) showed moderate to high affinity for both σ 1 and σ 2 receptors. Dextrorotatory isomers with the same configuration of 3-phenylpiperidines to C-1 carbon linked to the phenyl ring showed a better affinity and selectivity for σ 1 receptors compared to the respective levorotatory isomers. Compounds (+)-14 and (+)-15 displayed very high affinity for σ 1 (Ki = 0.9 and 2.3 nM respectively) but low selectivity for receptor subtypes. Compound (+)-18 with N-phenethyl substituent embodies the highest selectivity for σ 1 receptors.
Introduction
Sigma (σ) receptors are typical binding sites interacting with several psychoactive drugs including haloperidol, benzomorphans and phencyclidine. [1] [2] [3] [4] [5] The σ 1 subtype exhibits high affinity for (+)-benzomorphans such as (+)-pentazocine and (+)-N-allylnormetazocine (SKF-10,047) and a reduced affinity for the respective (-)-enantiomers. Based on animal model studies, this subtype seems to be involved in cocaine induced behavioral changes, in opiate induced analgesia, steroid-induced mental disturbances and alterations in immune functions. Using a different synthetic approach, 1-phenyl-3-azabicyclo[3.1.0]hexanes were previously reported by Fanshawe et al. as non-narcotic analgesic compounds and as agents for treating depression and chemical dependencies. [13] [14] [15] Although some of these effects might be related to a possible interaction with σ receptors, to date no affinity binding data have been reported about these compounds. In these studies we report our strategy to synthesize 1-phenyl-3-azabicyclo[3.1.0]hexane derivatives and structure affinity relationships for σ 1 and σ 2 receptors. 
Results and Discussion
Chemistry Racemic methyl 2-(bromomethyl)-1-phenylcyclopropanecarboxylate (±)-1 and its enantiomers (+)-and (-)-1 were synthesized according to a previously reported procedure.
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Treatment of 1 with NaN 3 in DMF gave azido intermediate 2 (Scheme 1). Subsequently, reduction of 2 with sodium hydrogentelluride (NaTeH) 16 in ethanol and internal cyclization provided a good yield of lactam 3. The NaTeH was readily prepared from tellurium and NaBH 4 as reported by Barton and McCombie. 17 Treatment of 3 with diborane in anhydrous THF gave 1-phenyl-3-azabicyclo[3.1.0]hexane 4. The final compound 12 was prepared by alkylation of 4 with commercially available 1-bromo-3-methylbut-2-ene. Intermediates 5-11 were synthesized by treatment of commercially available amines with methyl bromoester 1. Compounds 13-20 were obtained by reduction with diborane in anhydrous THF of the respective lactams (5-11). All structures of synthesized compounds were fully consistent with 1 H-NMR and 13 C-NMR spectral data. Table 1 . These data show that secondary amine 4 did not interact significantly with σ   and σ 2 receptors (Ki > 10,000). However, nitrogen substitution with propyl or 2-methyl-2-butene led to compounds (13 and 12 respectively) able to interact with σ receptors. Specifically, compound 12 showed a good affinity with a slight preference for σ 1 receptor subtypes. Ncyclohexyl substitution gave compound 14 with the highest affinity in the racemic series. These results were similar to the N-substitution on 3-phenylpiperidine, octahydrobenzo[f]quinoline and cis-benzomorphan derivatives 12, 18 which revealed an increase in binding affinity when nitrogen of the secondary amines was substituted with bulk alkyl substituents. Compared to 14, introduction of a methylene spacer between the nitrogen and cyclohexyl residue (15) decreased by six time the binding affinity for σ 1 receptors and to a greater extent for σ 2 . The substitution of cyclohexane of 15 with more bulk adamantane (16) induced a strong reduction of σ 1 and σ 2 receptor affinity.
The benzyl derivative 17 revealed a lower σ binding affinity compared with the respective cycloalkyl 15. Moreover, an increase of the methylenic chain in phenylethyl and phenylpropyl derivatives (18 and 19 respectively) induced different effects on affinity and selectivity. In particular, 18 showed an improved affinity and selectivity for σ 1 subtypes, whereas compound 19 displayed a slight preference for σ 2 receptors.
Considering the better binding profile of racemic compounds 14, 15, 18 and 19 we also evaluated the affinity of the respective enantiomers ( Table 2 ). The binding affinity data showed that (+)-(1R,5S)-isomers have higher affinity for the σ 1 receptor compared with (-)-(1S,5R)-isomers. Specifically, (+)-(1R,5S)-14 displayed a slight improvement of affinity and selectivity for σ 1 receptors compared with the respective (-)-(1S,5R)-isomer which showed a little preference for σ 2 subtypes.
Enantiomers (+)-(1R,5S)-and (-)-(1S,5R)-15 increased their binding affinity for both σ 1 and σ 2 subtypes and thus with no substantial increase of selectivity with respect to the racemic mixture.
Conversely to these results, an improved selectivity for σ 1 receptors was obtained with Nphenethyl derivative (+)-(1R,5S)-18 which had the highest selectivity of the series. The respective isomer (-)-(1S,5R)-18 showing the same decrease of affinity for both σ 1 and σ 2 receptors did not provide significant results compared with racemic mixture. The preference of (±)-19 for σ 2 receptors was not confirmed in the respective enantiomers. In particular (+)-(1R,5S)-and (-)-(1S,5R)-19 increased both σ 1 and σ 2 receptor affinity with a reversed selectivity compared to (±)-19. Moreover, the evaluation of binding affinity of Nphenethyl derivative (+)-(1R,5S)-and (-)-(1S,5R)-18 and phenylpropyl (+)-(1R,5S)-and (-)-(1S,5R)-19, provided evidence that the increase of methylenic chain spacer was more critical for σ 2 with respect to σ 1 receptors.
In conclusion, in these paper we present novel 1-phenyl-3-azabicyclo[3.1.0]hexane derivatives capable of interacting with moderate to high affinity with sigma receptors. Conformational restriction of phenyl-3-azabicyclo[3.1.0]hexane derivatives compared with 3-phenylpiperidine did not produce compounds with high selectivity for σ receptor subtypes in this series but like (+)-and (-)-3-PPP (3-phenylpropylpiperidine) only a slight preference for σ 1 receptors. However, the very high affinity of compounds (+)-(1R,5S)-14 and (+)-(1S,5R)-15 gave a good starting point to design new potential σ 1 and σ 2 selective ligands.
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Page 161 © ARKAT USA, Inc Radiology and binding assays σ 1 -Site binding assays were carried out on guinea pig brain membranes as previously reported. 19 Briefly, each tube containing 500 µg of membrane protein was incubated for 150 min at 37 °C with [ 3 H]-(+)-pentazocine (3 nM) in 50 mM Tris-HCl pH 7.4. Non-specific binding was determined using 10 µM haloperidol. The final volume of the assay samples was 1.0 mL. After incubation the samples were filter through a Schleicher & Schnell GF 6 glass fiber filter which had been pre-soaked for 1 h in a 0.5% poly(ethylenimine) solution. Filters were washed twice with 4 ml of ice-cold buffer before transfer to scintillation vials.
σ 2 -Site binding assays were carried out on guinea pig brain membranes, prepared as previously described by Mach et al. 20 . The membranes were incubated with [ to σ 1 sites) . The final volume of the assay sample was 0.5 mL. Incubations proceeded for 2 h at room temperature in 50 mM Tris-HCl, pH 8.0. Non-specific binding was evaluated in the presence of 5 µM DTG. Each assay was terminated by the addition of ice-cold 10 mM Tris-HCl pH 8.0, followed by filtration through a poly(ethylenimine) (0.5% w/v) treated GF 6 glass fiber filter which were washed twice with 4 ml of ice-cold buffer before transfer to scintillation vials. The Ki values were calculated using the EBDA/LIGAND program 21 purchased from Elsevier/Biosoft.
